PPARG and inflammatory bowel disease: IBD, a chronic debilitating condition comprising ulcerative colitis (UC) and Crohn’s disease (CD), is characterized by immune imbalance and continuous inflammation originated in the intestines and is one of such disorders where this approach for repurposing of PPARγ ligands would be feasible.